Biologics in Pediatric Rheumatology: Quo Vadis?
The past two decades have brought immense satisfaction to pediatric rheumatologists and families of children with rheumatologic diseases. We have been able to better classify, recognize, and diagnose rheumatologic diseases, but most importantly, the discovery of biologic therapies and their efficacy and relative safety in treating multiple rheumatologic conditions, improving quality of life for the patients we care for. We will review the advances of the past two decades and discuss potential areas for new discoveries.
Division of Pediatric Rheumatology, The Children's Hospital at Montefiore, 3415 Bainbridge Avenue, Bronx, NY, 10467, USA. ysterba@montefiore.org.
Yonit
Y
Sterba
Division of Pediatric Rheumatology, The Children's Hospital at Montefiore, 3415 Bainbridge Avenue, Bronx, NY, 10467, USA.
Norman
N
Ilowite
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D001688:Biological Products / Q000627:therapeutic use*; D002648:Child; D006801:Humans; D010372:Pediatrics; D011788:Quality of Life; D012219:Rheumatology
D018501:Antirheumatic Agents; D001688:Biological Products
Abatacept; IL-1 inhibitors; IL-6 inhibitors; Juvenile idiopathic arthritis (JIA); Rituximab; TNF inhibitors; Tofacitinib